Amino acid-derived lipid enables inhaled lung base editing and restores CFTR function in cystic fibrosis models
Delivering editing cargo to lung epithelial cells
Nanoparticles made with an amino acid-derived lipid delivered gene-editing cargo to lung epithelial cells and restored CFTR expression and chloride ion channel function in preclinical cystic fibrosis models. Published in Nature Materials, the study demonstrates the potential of inhaled lung base editing using an ionizable lipid called CHCha-10. The findings come from human airway epithelial cells, mouse-derived intestinal organoids, and cystic fibrosis mice; the study did not establish therapeutic efficacy in patients.
Applying CRISPR-based genome editing to lung disease requires delivery of editing cargo to target cells. The researchers focused on amino acid-derived ionizable lipids as materials to address this delivery challenge. Their approach combined different amino acid scaffolds to generate candidates and examine how structure affected delivery performance.
From screening 960 lipids to restoring CFTR function
The researchers used combinatorial synthesis to produce 960 ionizable lipids from proteinogenic α-amino acids and other α-amino acid scaffolds. High-throughput screening and structure–function analysis then identified CHCha-10, a lipid derived from a cyclohexyl amino acid. This lipid formed biodegradable nanoparticles that delivered gene-editing cargo in messenger RNA (mRNA) form to lung epithelial cells.
Delivery performance was studied in mice and ferrets. After intratracheal administration, CHCha-10 nanoparticles showed enhanced mucus penetration and epithelial cell-specific delivery. However, the supplied abstract does not specify a comparator or fold improvement, making it difficult to quantify how much better it performs than other delivery vehicles. Delivery properties observed in these two animal species should not be interpreted as evidence of correction of a cystic fibrosis mutation in ferrets.
Functional validation targeted the CFTR G542X mutation. The researchers delivered mRNA encoding an adenine base editor along with guide RNA and reported in vivo lung base editing by inhalation. According to the abstract, CFTR expression and chloride ion channel function were restored in human airway epithelial cells carrying the G542X mutation, mouse-derived intestinal organoids, and the lungs of cystic fibrosis mice. The intestinal organoids are a separate validation model, distinct from lung tissue. The available materials do not report editing efficiency or the extent of functional recovery for each model.
Delivery vehicle design and the gap to clinical use
The study links the development of a material for delivering editing RNA to the lungs with restoration of a disease-associated gene’s function. The researchers interpret the approach of combining amino acid scaffolds as a potential foundation for developing delivery vehicles for RNA-based lung gene correction. The central finding is preclinical proof of concept targeting a specific CFTR mutation.
Whether this approach can be applied in humans requires separate investigation. The available abstract alone does not allow assessment of effect duration, repeat-dosing feasibility, toxicity, or off-target editing. It also remains unconfirmed whether restored CFTR function would improve respiratory symptoms in patients. Follow-up studies will need to assess safety and the durability of functional recovery alongside delivery and editing performance.
Source: the article’s bibliographic record and abstract in Europe PMC.
CRISPR-based gene editing holds promise for treating genetic diseases, yet its application to lung disorders has been hindered by the challenges of pulmonary delivery. Inspired by the modularity and biocompatibility of amino acid-derived chemistries, we report the combinatorial synthesis of 960 ionizable lipids incorporating chemically diverse backbones from both proteinogenic and non-proteinogenic α-amino acids. Through high-throughput screening and structure-function analysis, we identify CHCha-10, a cyclohexyl amino acid-derived lipid that forms biodegradable nanoparticles capable of efficiently delivering mRNA-based gene editors to lung epithelial cells. Following intratracheal administration, CHCha-10 nanoparticles exhibit enhanced mucus penetration and epithelial-specific transfection in both mice and ferrets. Here, as a functional application, we demonstrate in vivo base editing in the lung via inhalation. Delivery of adenine base editor mRNA and guide RNA targeting the CFTR G542X mutation restores CFTR expression and chloride channel function in G542X human airway epithelial cells, mouse-derived intestinal organoids and the lungs of cystic fibrosis mice. This work establishes a chemically modular design framework for ionizable lipids and a translatable platform for RNA-based pulmonary gene correction.
In follow-up studies targeting the CFTR G542X mutation in cystic fibrosis, CHCha-10 could be considered as a candidate for delivering editing RNA to the lungs. It may inform study designs that assess not only whether the cargo reaches airway cells, but also whether correction of the target restores CFTR expression and chloride ion channel function. The work also offers a starting point for developing lipid materials by comparing candidates with different amino acid scaffolds. However, the abstract provides no model-specific editing efficiencies or degrees of recovery, making it difficult to judge the relative merits of candidates or the performance required for treatment. Discussing clinical development will require further investigation of delivery feasibility in human lungs, effect duration, repeat dosing, and safety.